Evaluation of Regenerative Endodontic Treatment for Immature Teeth

September 29, 2025 updated by: Hisham Mahmoud Hamdy Abada, Kafrelsheikh University

Evaluation of Regenerative Endodontic Treatment for Immature Teeth Using Two Different Forms of Demineralized Dentin Matrix and RetroMTA: Randomized Controlled Clinical Trial

The goal of this clinical trial is to evaluate if regenerative endodontic treatment using two different forms of demineralized dentin matrix (DDM) can effectively treat immature permanent single-rooted teeth compared to treatment using RetroMTA in patients aged 9 to 15 years. The main questions it aims to answer are:

Does the use of DDM improve clinical and radiographic outcomes such as root length, dentinal wall thickness, and apex closure?

Is DDM a viable bioactive alternative to RetroMTA as a coronal sealing material in regenerative endodontic procedures?

Researchers will compare three groups: one using RetroMTA, one using a DDM-TheraCal LC mixture, and one using TDM-Hydrogel, to see if these materials differ in their effects on regenerative outcomes.

Participants will:

Undergo two treatment visits including canal disinfection, induction of bleeding to form a blood clot scaffold,

Receive placement of one of the study materials over the blood clot as a coronal barrier,

Have clinical examinations and CBCT imaging at baseline and multiple follow-ups up to 12 months to assess treatment success through signs, symptoms, and radiographic changes.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study was conducted as a split-mouth randomized clinical trial, approved by research ethics committee, Faculty of Dentistry, Kafrelsheikh University, and carried out at Endodontic Department, Faculty of Dentistry, Kafrelsheikh University. 36 patients of both sexes aged from 9 to 15 years old were selected with an immature teeth with teeth diagnosed as either vital (asymptomatic irreversible pulpitis or symptomatic irreversible pulpitis and the bleeding didn't stop after 5 minutes application of hemostatic agent) or non-vital pulp are indicated for regenerative endodontic procedure.

Patients will be divided randomly into three equal groups (n = 12):

Group 1(control group): Revascularization will be done using blood clot and RetroMTA as coronal barrier.

Group 2: Revascularization will be done using blood clot and DDM-TheraCal LC mixture paste as coronal barrier.

Group 3: Revascularization will be done using blood clot and TDM-Hydrogel as coronal barrier.

CBCT image will be obtained for baseline records before treatment and after placement of the final resin restoration, then the patients will be recalled after 3, 6, 9 and 12 months for evaluating any changes in dentin bridge formation, root length, root canal width, apex diameter and lesion size if present.

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Systemically healthy patients (i.e., free of any systemic diseases).
  • Patients presenting with immature permanent single-rooted teeth.
  • Age: 9 -15 years.
  • Teeth diagnosed as either vital (asymptomatic irreversible pulpitis or symptomatic irreversible pulpitis and the bleeding didn't stop after 5 minutes application of hemostatic agent) or non-vital pulp.

Exclusion Criteria:

  • Patients who are allergic to any drugs used in this study or with systemic illness
  • Teeth that are grossly decayed or fractured and require post and core as final restorations
  • Presence of periodontal pockets greater than 4 mm.
  • Radiographical evidence of apical foramen less than 1 mm.
  • Presence of periapical radiolucency exceeding 10 mm.
  • Presence of external or internal root resorption.
  • Patients with a history of major surgeries like cardiac, kidney transplantation, haemodialysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: treated hyman dentin matrix hydrogel
material used for regenerative dentistry
material used for regenerative dentistry
material used for regenerative dentistry
Active Comparator: Theracal LC- Demineralized dentina matrix combination
material used for regenerative dentistry
material used for regenerative dentistry
material used for regenerative dentistry
Other Names:
  • demineralized dentin matrix
Active Comparator: RetroMTA
material used for regenerative dentistry
material used for regenerative dentistry
material used for regenerative dentistry
Other Names:
  • demineralized dentin matrix

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maturation of root
Time Frame: year
root length increase, root width increase, apical formane closes and dentinal bridge formation over regenerated pulp
year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
resolve of apical lesion if present
Time Frame: 1 year
if there is any apical lesion, it will resolve and new bone formation takes place.
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
regain sensibility of pulp
Time Frame: 1 t 2 years
nerve supply of pulp is regenerated with time but not primary outcome
1 t 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hisham Abada, Doctors, Academic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2025

Primary Completion (Estimated)

September 20, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

September 29, 2025

First Submitted That Met QC Criteria

September 29, 2025

First Posted (Estimated)

October 7, 2025

Study Record Updates

Last Update Posted (Estimated)

October 7, 2025

Last Update Submitted That Met QC Criteria

September 29, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 663

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulpal Necrosis

Clinical Trials on Theracal LC - Demineralized dentin matrix combination

Search Similar Trials